Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apimeds Pharmaceuticals UsAPUS +5.15%14 EV-to-EBITDA is -0.44 as of Jul. 21, 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 742 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 134770.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Apimeds Pharmaceuticals Us's enterprise value is $17.39 Mil.
Apimeds Pharmaceuticals Us's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.53 Mil. Therefore, Apimeds Pharmaceuticals Us's EV-to-EBITDA for today is -0.44.
The historical rank and industry rank for Apimeds Pharmaceuticals Us's EV-to-EBITDA or its related term are showing as below:
APUS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.44 Med: 0 Max: 0
Current: -0.44
APUS's EV-to-EBITDA is ranked worse than 100% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.99
vs APUS: -0.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Apimeds Pharmaceuticals Us (AMEX:APUS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Apimeds Pharmaceuticals Us's PE Ratio (TTM) for today is calculated as:
Apimeds Pharmaceuticals Us's share price for today is $0.67999.
Apimeds Pharmaceuticals Us's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's EV-to-EBITDA falls into.
Apimeds Pharmaceuticals Us's current Enterprise Value is $17.39 Mil.
Apimeds Pharmaceuticals Us's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apimeds Pharmaceuticals Us (APUS) has a EV-to-EBITDA of -0.44 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Apimeds Pharmaceuticals Us. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 742 companies in the Drug Manufacturers industry.
Is Apimeds Pharmaceuticals Us' EV-to-EBITDA too high?
Apimeds Pharmaceuticals Us' current EV-to-EBITDA is -0.44. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' EV-to-EBITDA compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 742 companies for EV-to-EBITDA. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.99, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Apimeds Pharmaceuticals Us. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current EV-to-EBITDA is -0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current EV-to-EBITDA of -0.44. The current EV-to-EBITDA is -0.44. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current EV-to-EBITDA is -0.44 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score
Get the complete analysis for APUS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
